Resources
Quality
FDA Registration
Aquila Bioscience have been successfully registered as a foreign manufacturing facility with FDA under Owner/ Operator Number 10074735
The ABD Wipe product is registered with FDA under device listing D405606.
Aquila Bioscience are now permitted to market and sell the ABD Device in the US market.
CE Mark
Path to CE mark is underway and is expected to be completed in 2021
Accreditation
NeoVirTech – French Labratory of expertise has proven the efficiency of the ABD Device in its ability to capture and remove up to 99.99% of SARS CoV-2 from the human skin.Â
ProShield Mask Spray Press
Aquila Bioscience in the News
Product Developments
11th of March 2021
Irish Medtech Company develops mask spray that blocks 99% of pathogens
Aquila Bioscience has developed a groundbreaking new barrier spray making re-usable masks up to 99% effective at blocking airborne pathogens and particles.
ProShield Mask Spray has been developed by scientists and researchers at Aquila Bioscience to create a safe, nanofibre protective coating on material, an added defence against airborne pathogens.
Driven by the need to increase protection of reusable masks, to reduce dependence on disposable masks and ultimately to protect the environment by reducing plastic waste, we have successfully applied our signature technology to ProShield Mask Spray.
Reports
28th October 2020
Irish Company Develop Technology Proven to Remove 99.99% of Coronavirus from Human Skin
Aquila Bioscience has successfully proven that its breakthrough Pathogen Capturing Technology safely removes 99.99% of SARS-CoV-2 from human skin. This is the first time a nature inspired, safe and non-toxic technology that is free from all harmful chemicals, has been proven to remove COVID-19 with such efficiency. The results show that this novel technology is equally if not more effective as the highest performing chemical-based methods currently on the market but without any of the environmental or health problems.
8th June 2020
Aquila Bioscience is selected for EIC Accelerator Funding
Aquila Bioscience has developed revolutionary decontamination technology that helps protect people from dangerous pathogens and other viral infections like coronavirus. We are delighted to receive funding from EIC which allows us to substantially scale up production and deliver this technology more quickly to frontline and other workers in Ireland and across the globe. This technology will make it safer for people to return to work and help get Ireland’s economy moving again.
29th May 2020
Aquila Bioscience Registered with FDA
Aquila Bioscience have been successfully registered as a foreign manufacturing facility with FDA under Owner/ Operator Number 10074735
The ABD Wipe product is registered with FDA under device listing D405606.
Aquila Bioscience are now permitted to market and sell the ABD Device in the US market.
